PSMA-Directed Therapies in Prostate Cancer

Video

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Clinical Pearls:

  • PSMA (Prostate Specific Membrane Antigen) is a protein distinct from PSA in that it is a folate transporter and is expressed in about 90% of prostate cancer specimens
  • PSMA seems to be upregulated after hormone therapy and may be downregulated as patients progress in the pathway of castration resistance
  • PSMA is a target of ProstaScint, an FDA approved agent for imaging prostate cancer
  • PSMA is being used as an imaging agent and a therapeutic target
  • Researchers have been looking into combining anti-PSMA antibody with an agent that targets tubulin, which may deliver chemotherapy more effectively
  • The anti-PSMA antibody has demonstrated activity in patients who failed docetaxel and cabazitaxel
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content